Navigation Links
China Biologic Products Enters into a Strategic Research and Development Agreement with IBT of CAMS
Date:9/24/2009

TAI'AN, China, Sept. 24 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that on September 11, 2009, the Company entered into a strategic research and development agreement with the Institute of Blood Transfusion (the "IBT") based in Chengdu, Sichuan Province, to strengthen the Company's research and development capabilities and manufacturing processes. IBT is a division of the Chinese Academy of Medical Sciences and Peking Union Medical College ("CAMS").

The IBT is a leading research institute in China, specializing in a variety of plasma-based research including research on the safety of blood transfusions, blood immunology, transfusion disposable materials, blood biochemistry and molecular biology. China Biologic's collaboration with IBT will include the use of IBT's technology to enhance safe and efficient plasma collection, and increase the range of plasma-derivative products that can be manufactured by the Company. The agreement also entitles China Biologic to utilize IBT's platform technologies, including its recombinant protein therapeutics, monoclonal antibody technology and diagnostics.

China Biologic will collaborate by providing partial funding, plasma, the use of its manufacturing facilities, and access to its research and development resources. IBT will provide specialized training and education to China Biologic's research staff, and will procure additional funding from national and provincial funding bodies. In addition, China Biologic is entitled to the priority purchase rights to commercialize any new technologies or products that result from the collaboration.

"We are committed to being a technology leader in the area of plasma-based pharmaceuticals and we constantly seek to improve
'/>"/>

SOURCE China Biologic Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. China Agro-Technology Holdings Reorganized
2. China Agro-Technology Holdings Announces Launch of Agricultural Biotech Website
3. Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
4. China Biologic Products to Attend at Susquehannas Third Annual Beijing Management Summit
5. China Biologic Products Appoints Director of Research and Development
6. China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit
7. Fauve Intertrade Signs Major Energy Contracts in China
8. China Biologic Products to Participate in the Rodman & Renshaw Annual Global Investment Conference
9. China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes
10. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
11. AOBOs Products Included in Chinas Essential Drug List
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/19/2014)... 2014 The Latin American hardware encryption ... Latin America with analysis and forecast of revenue. This ... is expected to reach $2,366.8 million by 2018, at ... Browse through the TOC of the Latin American hardware ... in-depth analysis provided. It also provides a glimpse of ...
(Date:10/19/2014)... The Asian Automatic patient billing report ... and forecast of revenue. The Automatic patient billing market ... million by 2018, at a developing CAGR of 7.2% ... of the Asian Automatic patient billing market, to get ... provides a glimpse of the segmentation of this market ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... , ROCKVILLE, Md. , Aug. 6 ... today the appointment of Richard Douglas , Ph.D. to ... President, Corporate Development at Genzyme Corp.  As a leader of ... numerous acquisitions, licenses, joint ventures and strategic alliances as well ...
... Arizona State University researchers will get support from the ... next generations of lasers and infrared photodetectors. ... for an array of defense and commercial applications. ... Office grant through the defense department,s Multidisciplinary University Research ...
... Vicept Therapeutics, Inc., a privately held specialty biopharmaceutical company, announced ... the Company,s lead product V-101, a topical cream under investigation for ... , , ... crossover clinical trial of 22 patients with rosacea was designed to ...
Cached Biology Technology:NOVAVAX Elects Richard H. Douglas to its Board of Directors 2NOVAVAX Elects Richard H. Douglas to its Board of Directors 3Looking to leap forward on laser and photodetector technologies 2Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea 2Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea 3
(Date:10/15/2014)... , Oct. 15, 2014 Sandata ... for home and community-based care, today announced it ... implementing Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™) ... is a home health company founded in 1996 ... . The study details ...
(Date:10/15/2014)... of Life, is a non-traditional biophysics textbook and it ... is a journey of discovery into biological systems and ... biological regulation. It is about how our genes make ... the billions of cells in an organism. It quantifies ... principles, which can be found on both large and ...
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2New book about life as seen from physics 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... 1, 2011 A pathway whereby bacteria communicate with ... Hebrew University of Jerusalem. The discovery has important implications ... bacteria in the body. Bacteria are known to ... of extracellular signalling molecules, said Prof. Sigal Ben-Yehuda of ...
... is known to have cancer-protective properties, and shift work ... production. Shift work has been thought to have important ... increased risk of several cancers including breast, endometrial, prostate, ... study, researchers at Brigham and Women,s Hospital (BWH) found ...
... SEATTLE Twelve graduate students from institutes throughout ... Harold M. Weintraub Graduate Student Award sponsored by the ... Nominations were solicited internationally; the winners were selected on ... their work. , The recipients, all advanced students at ...
Cached Biology News:Shift work may be associated with decreased risk of skin cancer 22011 Harold M. Weintraub Graduate Student Award recipients announced 22011 Harold M. Weintraub Graduate Student Award recipients announced 3
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
DL-Dithiothreitol (Clelands Reagent) ,PROTEASE FREE!! ,Molecular Biology Grade ,PRODUCT MUST SHIP NEXT DAY DURING HOT SUMMER MONTHS. ,C 4 H 10 O 2 S 2 ,Molecular Weight: 154.25 ,CAS RN: [27565-...
DTT 50 l...
...
Biology Products: